Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00643058 · ClinicalTrials.gov registry record · Phase 1

Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II

A Phase 1 study, sponsored by John Sundy.

Terminated
Registry status
Phase 1
Development phase
70
Enrollment target

NCT00643058: Clinical Trial Phase 1 study, sponsored by John Sundy.

NCT00643058 is a Phase 1 study that was terminated before completion, run by John Sundy. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00643058, a Phase 1 study, was terminated before completion, sponsored by John Sundy.

TERMINATED
Registry status
Phase 1
Development phase
70 participants
Enrollment target

Study Summary

The purpose of the study is to determine the role of nitric oxide (NO) in asthma and to characterize the symptoms associated with inhaled endotoxin (lipopolysaccharide \[LPS\]) in normal subjects. In this study, we will determine the effect of inhaled endotoxin on exhaled NO in healthy African Americans, with and without NOS2 promoter polymorphisms. The protocol described in this submission will involve the use of NIH Clinical Center Reference Endotoxin which has been approved by the FDA under IND BB-IND-10035.

Interventions

  • BIOLOGICAL LPS endotoxin

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2003-04
Est. Completion 2009-12
Phase Phase 1
John Sundy

6 total trials

Why NCT00643058 stopped before completion

NCT00643058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).

The record links to 0 conditions, and to 1 intervention - of which LPS endotoxin is the first listed.

NCT00643058 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00643058 about?

NCT00643058 is a clinical study titled "Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II". The purpose of the study is to determine the role of nitric oxide (NO) in asthma and to characterize the symptoms associated with inhaled endotoxin (lipopolysaccharide \[LPS\]) in normal subjects. In this study, we will determine the effect of inhaled endotoxin on exhaled NO in healthy African Ameri...

What is the current status of trial NCT00643058?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2003-04. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00643058?

The interventions under investigation include: LPS endotoxin (BIOLOGICAL).

Who is sponsoring clinical trial NCT00643058?

This trial is sponsored by John Sundy, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00643058's enrollment target sits among peer trials

70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00643058, the US trial registry maintained by the National Library of Medicine. NCT00643058 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.